Mylan's (MYL) EpiPen Settlement with U.S. DOJ Seen as 'Significant' by BTIG; 'Buy' Rating Affirmed
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) in Advanced Talks to Acquire B/E Aerospace (BEAV) - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
BTIG affirms Mylan N.V. (Nasdaq: MYL) at Buy with a price target of $55 after the company announced that its subsidiary, Mylan Inc., has agreed to the terms of a $465 million settlement with the U.S. Department of Justice and other government agencies that will resolve questions that have been raised about the classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector for purposes of the Medicaid Drug Rebate Program.
The firm commented,
We believe this settlement with the DOJ is significant and may put the EpiPen pricing controversy to rest. While a separate FTC investigation could still move forward, our channel checks with health policy contacts over the weekend suggest there is a low probability for that to occur given the size of the settlement. While we have lowered our CY16 and CY17 EPS forecasts to $4.70 and $5.58, to reflect lower Epipen sales going forward, we maintain our Buy rating on MYL shares based on the heavily discounted valuation and its strong position as a global generics Co.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Proofpoint (PFPT) Still the Name to Own Following Q3 Results; BTIG Affirms at 'Buy'
- Imperial Capital Raises Price Target on Proofpoint (PFPT) Following Strong 3Q Results
Create E-mail Alert Related CategoriesAnalyst Comments, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!